A newly developed AI can predict which diseases specific genetic mutations are likely to cause, not just whether they are harmful. The breakthrough could speed up diagnoses and open new paths for ...

Last week, as fashion fans watched model Bhavitha Mandava open Chanel’s 2025 Métiers d’art show—staged on a New York City subway platform—they had no idea just how accidentally appropriate the setting ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...

A new AI model called popEVE can predict how likely each variant in a patient’s genome is to cause disease. The team is testing popEVE in clinical settings to see if it can speed accurate diagnoses of ...

Forbes contributors publish independent expert analyses and insights. We set an example for a better future via education and research. The possible shift back to entirely in-person work has sparked a ...

Across the planet, animals are increasingly suffering from chronic illnesses once seen only in humans. Cats, dogs, cows, and even marine life are facing rising rates of cancer, diabetes, arthritis, ...

Assess how research findings about the function of disease-causing variants (e.g loss of function versus gain of function) can suggest some future goals for therapy (gene therapy, gene editing, ...

Tesla faces competition from cheaper European, Chinese EVs More than 25 new electric models to launch in Europe next year Tesla trying to reverse steep market-share losses in Europe Oct 8 (Reuters) - ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

Tesla has unveiled the long-promised cheaper versions of its two main cars, dubbed the Model 3 Standard and Model Y Standard, after the expiration of the $7,500 tax credit for American buyers of most ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...